Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Zon

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2008
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sitesRobin Zon, Neal J Meropol, Robert B Catalano, et al.
The New England Journal of Medicine|May 24, 2018
Rationale, Opportunities, and Reality of Biosimilar MedicationsGary H Lyman, Robin Zon, R Donald Harvey, et al.
Journal of Oncology Practice|February 16, 2018
Reimbursement for Preventive Counseling ServicesRobin Zon, Elaine Towle, Mandy Ndoping, et al.
Investigational New Drugs|July 2, 2013
A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109Lida A Mina, Menggang Yu, Cynthia Johnson, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|March 31, 2025
A New Approach to Cancer Second Opinions: Overcoming the Challenges of Conventional Oncology Practice by Providing Education to Patients and PhysiciansWilliam L Barrett, Philip D Leming, Jillian Hunt, et al.
Proteomics. Clinical Applications|December 8, 2010
Intrinsic subtype-associated changes in the plasma proteome in breast cancerHarikrishna Nakshatri, Guihong Qi, Jinsam You, et al.
Journal of Oncology Practice|August 15, 2013
Qualitative analysis of practicing oncologists' attitudes and experiences regarding collection of patient-reported outcomesReshma Jagsi, Anne Chiang, Blase N Polite, et al.
American Journal of Clinical Oncology|December 16, 2014
Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130Shadia I Jalal, Nasser Hanna, Robin Zon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2018
American Society of Clinical Oncology Statement: Biosimilars in OncologyGary H Lyman, Edward Balaban, Michael Diaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysisNoah M Hahn, Sharon Marsh, William Fisher, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2008
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sitesRobin Zon, Neal J Meropol, Robert B Catalano, et al.
The New England Journal of Medicine|May 24, 2018
Rationale, Opportunities, and Reality of Biosimilar MedicationsGary H Lyman, Robin Zon, R Donald Harvey, et al.
Journal of Oncology Practice|February 16, 2018
Reimbursement for Preventive Counseling ServicesRobin Zon, Elaine Towle, Mandy Ndoping, et al.
Investigational New Drugs|July 2, 2013
A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109Lida A Mina, Menggang Yu, Cynthia Johnson, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|March 31, 2025
A New Approach to Cancer Second Opinions: Overcoming the Challenges of Conventional Oncology Practice by Providing Education to Patients and PhysiciansWilliam L Barrett, Philip D Leming, Jillian Hunt, et al.
Proteomics. Clinical Applications|December 8, 2010
Intrinsic subtype-associated changes in the plasma proteome in breast cancerHarikrishna Nakshatri, Guihong Qi, Jinsam You, et al.
Journal of Oncology Practice|August 15, 2013
Qualitative analysis of practicing oncologists' attitudes and experiences regarding collection of patient-reported outcomesReshma Jagsi, Anne Chiang, Blase N Polite, et al.
American Journal of Clinical Oncology|December 16, 2014
Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130Shadia I Jalal, Nasser Hanna, Robin Zon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2018
American Society of Clinical Oncology Statement: Biosimilars in OncologyGary H Lyman, Edward Balaban, Michael Diaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysisNoah M Hahn, Sharon Marsh, William Fisher, et al.
Pageof 4